Prometheus Biosciences Stock Forecast, Price & News

Prometheus Biosciences (NASDAQ:RXDX) Frequently Asked Questions

Is Prometheus Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prometheus Biosciences stock.
View analyst ratings for Prometheus Biosciences or view top-rated stocks.

Are investors shorting Prometheus Biosciences?

Prometheus Biosciences saw a increase in short interest in December. As of December 31st, there was short interest totaling 1,580,000 shares, an increase of 45.0% from the December 15th total of 1,090,000 shares. Based on an average daily volume of 256,800 shares, the short-interest ratio is presently 6.2 days. Currently, 6.2% of the company's shares are short sold.
View Prometheus Biosciences' Short Interest.

When is Prometheus Biosciences' next earnings date?

Prometheus Biosciences is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for Prometheus Biosciences.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.11. The biopharmaceutical company had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.38 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 44.74% and a negative net margin of 2,696.67%.
View Prometheus Biosciences' earnings history.

What price target have analysts set for RXDX?

7 brokers have issued 1-year target prices for Prometheus Biosciences' shares. Their forecasts range from $30.00 to $50.00. On average, they expect Prometheus Biosciences' stock price to reach $42.86 in the next year. This suggests a possible upside of 23.6% from the stock's current price.
View analysts' price targets for Prometheus Biosciences or view top-rated stocks among Wall Street analysts.

Who are Prometheus Biosciences' key executives?

Prometheus Biosciences' management team includes the following people:

• Mr. Mark C. McKenna, Pres, CEO & Director (Age 41, Pay $1.51M)
• Dr. Keith W. Marshall M.B.A., MBA, Ph.D., CFO & Treasurer (Age 53, Pay $458.22k)
• Mr. Mark Stenhouse, Chief Operating Officer (Age 54)
• Dr. Allison Luo M.D., Chief Medical Officer (Age 48, Pay $586.13k)
• Mr. Gerald T. Proehl, Advisor
• Dr. Olivier Laurent Ph.D., Chief Technology Officer (Age 49)
• Dr. Laurens Kruidenier Ph.D., Chief Scientific Officer (Age 51)
• Ms. Noel Kurdi, VP of Investor Relations & Communications
• Mr. Timothy K. Andrews Esq., Gen. Counsel & Sec. (Age 42)
• Ms. Nori Ebersole, Chief People Officer (Age 57)

Who are some of Prometheus Biosciences' key competitors?

Some companies that are related to Prometheus Biosciences include Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Alkermes (ALKS), Intra-Cellular Therapies (ITCI), Cerevel Therapeutics (CERE), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), Galapagos (GLPG), Apellis Pharmaceuticals (APLS) and CureVac (CVAC).
View all of RXDX's competitors.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), (SLS), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Who are Prometheus Biosciences' major shareholders?

Prometheus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Strs Ohio (0.02%). Company insiders that own Prometheus Biosciences stock include Joseph C Papa, Mark Stenhouse and Perceptive Advisors Llc.
View institutional ownership trends for Prometheus Biosciences.

Which institutional investors are buying Prometheus Biosciences stock?

RXDX stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Prometheus Biosciences stock in the last two years include Joseph C Papa, Mark Stenhouse, and Perceptive Advisors Llc.
View insider buying and selling activity for Prometheus Biosciences or or view top insider-buying stocks.

How do I buy shares of Prometheus Biosciences?

Shares of RXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $34.68.

How much money does Prometheus Biosciences make?

Prometheus Biosciences has a market capitalization of $1.35 billion and generates $1.23 million in revenue each year.

How many employees does Prometheus Biosciences have?

Prometheus Biosciences employs 26 workers across the globe.

What is Prometheus Biosciences' official website?

The official website for Prometheus Biosciences is ignyta.com.

Where are Prometheus Biosciences' headquarters?

Prometheus Biosciences is headquartered at 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States.

How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via email at [email protected].